Dicationic fluorescent dyes
By introducing silicon or germanium to replace oxygen and imidazolium heterocycles to replace aryl groups in the structure of rhodamine, a dual-cationic fluorescent dye was designed, which solved the problems of decreased brightness and high background fluorescence in PCR technology. It achieved high brightness and low background fluorescence in the near-infrared spectral range, and is suitable for multiplex PCR and fluorescence microscopy.
Patent Information
- Application Number
- CN202080084948.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-12-09
- Filing Date
- 2020-12-07
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2040-12-07
AI Technical Summary
Existing fluorescent dyes exhibit decreased brightness and high background fluorescence in temperature-assisted signal generation PCR techniques, making it difficult to meet the requirements for multiplexing. In particular, the brightness of fluorophores is insufficient in the near-infrared spectral range, affecting detection sensitivity and accuracy.
By introducing silicon or germanium to replace oxygen atoms in the structure of rhodamine and replacing aryl groups with imidazole or imidazole-onium heterocycles, a dual-cationic fluorescent dye was designed to enhance water solubility and thermal stability and extend the spectrum to the near-infrared range.
This technology enables the enhancement of fluorescent dye brightness and reduction of background fluorescence under high-temperature conditions, expands the number of available fluorophores, and is suitable for multiplex PCR and fluorescence microscopy, thereby improving detection sensitivity and accuracy.
Smart Images

Figure CN114787286B_ABST
Abstract
Description
Technical Field
[0001] This invention relates generally to fluorescent compounds. In particular, this invention relates to rhodamine-based fluorescent dyes and methods for synthesizing and using these dyes. Background Technology
[0002] Customized fluorescent dyes are important for almost any analytical method that relies on fluorescence detection. In the life sciences, applications of fluorescent dyes range from real-time polymerase chain reaction (PCR) assays to fluorescence imaging techniques (including but not limited to fluorescence microscopy, single-molecule imaging, super-resolution microscopy, and cell labeling and tracking experiments).
[0003] Current advancements in analytical PCR target multiplexing, enabling the simultaneous detection and analysis of multiple targets in a sample. TAGS (Temperature-Assisted Signal Generation, disclosed in U.S. Patent Publication No. 2018 / 0073064, the entire contents of which are incorporated herein by reference) PCR is a multiplexing technique that measures multiple individual targets in each fluorescence channel by acquiring fluorescence data at different temperatures during thermal cycling. Therefore, TAGS multiplexing using two or three temperature channels can double or triple the number of resolvable targets per optical channel. In principle, this technique can be deployed on any quantitative PCR (qPCR) instrument capable of acquiring multiple fluorescence readings in each PCR cycle.
[0004] For any application relying on fluorescence detection, TAGS-based PCR requires bright dyes. The brightness of a fluorophore is defined by the product of its extinction coefficient and quantum yield. While the extinction coefficient determines the efficiency with which the fluorophore absorbs excitation light, the quantum yield is a measure of the number of photons emitted by the fluorophore in each excitation event. A common problem is that the overall brightness of the fluorophore tends to decrease significantly as we move toward the red end of the electromagnetic spectrum. Therefore, fluorophores in the near-infrared (NIR) spectral range (excitation and emission between 650 nm and 900 nm) are affected by the decrease in brightness, thus reducing the overall sensitivity of fluorescence-based applications.
[0005] In the context of PCR technology using tags, another requirement for fluorescent dyes is temperature-stable fluorescence emission. In particular, cyanide dyes such as Cy5, Cy5.5, or Cy7 exhibit significant brightness loss at elevated temperatures; this is inherent to polyacetylenic scaffolds with conformationally flexible chains containing conjugated double bonds.
[0006] Another requirement is to minimize background fluorescence from quenching probes (i.e., before they are cleaved by polymerase and not yet quenched). Background fluorescence is proportional to the number of PCR probes and causes an overall decrease in the measurable signal gain for each target. Therefore, the accumulation of residual fluorescence depends on the efficiency of quenching each fluorophore, and it is not only a function of molecular distance but also depends on the nature of the fluorophore-quencher pair.
[0007] The fluorescent dyes discussed in this disclosure address these key issues by introducing two structural modifications into the basic structure of common rhodamine. Oxygen is replaced by silicon or germanium, while the aryl group is exchanged for an imidazole or imidazole-onium heterocycle. The combined effect of these two modifications results in an anomalously red-shifted rhodamine with a size smaller than typical fluorophores in this wavelength range.
[0008] Water solubility of fluorescent dyes is a prerequisite for any application using water as the primary solvent, and is typically achieved by modifying the chromophore with negatively charged functional groups such as carboxylates or sulfates. Highly water-soluble chromophores have been obtained by introducing a second positive charge through the imidazolium moiety and by their compact size. Dye size, charge, and solubility are also important parameters in the context of fluorescence microscopy, significantly influencing penetration into tissues, cells, or organelles. For example, hydrophobicity can also lead to misleading fluorescence signals due to the aggregation or strong interaction between the target and the lipid bilayer.
[0009] The monocationic and dicationic dyes disclosed herein expand the number of available fluorophore scaffolds across the far-red to near-infrared spectral range. Their thermal stability, improved background fluorescence, and high water solubility enable their use in multiplex PCR and fluorescence microscopy. Summary of the Invention
[0010] This invention relates to novel rhodamine-based fluorescent dyes and methods for synthesizing and using these dyes.
[0011] In one aspect, the present invention provides a fluorescent dye of formula A:
[0012]
[0013] in:
[0014] X = Si, Ge, or C;
[0015] Y = Me, Et, iPr, or phenyl;
[0016] Z = any of the following:
[0017]
[0018] W = any of the following:
[0019]
[0020] R1 and R2 are any combination of the following terms:
[0021] and
[0022] L = H, SO3H, CONH2, CO2H, N3, or any part of a chemical functional group that has undergone a click.
[0023] In another aspect, the present invention provides a fluorescent dye of formula B:
[0024]
[0025] in:
[0026] X = Si, Ge, or C;
[0027] Y = Me, Et, iPr, or Ph;
[0028] Z = any of the following:
[0029]
[0030] R1 and R2 are any combination of the following terms:
[0031] and
[0032] L = H, SO3H, CONH2, CO2H, N3, or any part of a chemical functional group that has undergone a click.
[0033] In one embodiment, Z = any of the following:
[0034]
[0035] In another embodiment,
[0036]
[0037] In another aspect, the present invention provides fluorescent dyes selected from the following structures:
[0038]
[0039]
[0040] In another aspect, the present invention provides a method for preparing the fluorescent dye of the present invention. Hereinafter, the method for preparing the fluorescent dye may include the steps described in Examples 4, 5, 6, 7, or 8. In yet another aspect, the present invention provides uses of the fluorescent dye of the present invention. In one embodiment, the fluorescent dye of the present invention is used to detect one or more target nucleic acids in a sample by PCR assay (particularly in multiplex PCR assays). In another embodiment, the detection of target nucleic acids by the fluorescent dye of the present invention in a PCR assay can be performed at elevated temperatures (e.g., 65°C and above). In one embodiment, the fluorescent dye of the present invention is used to detect one or more target proteins in a tissue sample by immunohistochemistry. In another embodiment, the detection of target proteins in an immunohistochemical assay employs a primary or secondary antibody labeled with the fluorescent dye of the present invention. Attached Figure Description
[0041] Figure 1 The top figure shows the fluorescence spectra of two representative fluorescent dyes, numbers 29 and 30, and a commercially available reference dye. The bottom figure shows the temperature dependence of fluorescence for the same group of dyes. These results indicate that fluorescent dyes modified with azacyclobutane exhibit improved fluorescence thermal stability.
[0042] Figure 2A The image shows a UPLC chromatogram of a DNA probe labeled with a fluorescent dye after strain-promoted azide-alkyne cycloaddition (Click Chemistry). The reaction between DBCO and the azide moiety produces a triazole positional isomer, which is separated as a bimodal peak in the chromatogram.
[0043] Figure 2B : Shows from Figure 2A The absorption spectrum of the DNA-dye conjugate extracted from the UPLC chromatographic peak is shown.
[0044] Figure 3 The following figures show the qPCR amplification growth curves using DNA probes labeled with dye number 36 compared to those labeled with a commercially available reference dye. The original fluorescence signal was divided by the total gain (RFI). Results: Dye number 36 is qPCR compatible and exhibits improved quenching caused by BHQ-2 compared to commercially available dyes used in qPCR assays.
[0045] Figure 4 This image shows optical microscope images of immunohistochemically stained tonsil tissue sections at magnifications of 10x, 20x, and 40x (from left to right). (Image using CONFIRM) TMFormalin-fixed paraffin-embedded tissue sections were treated with anti-Ki-67 (30-9) rabbit monoclonal primary antibody (IgG). This antibody is an abundant biomarker in tonsillar tissue and targets the C-terminal portion of the Ki-67 antigen. Ki-67 is a nucleoprotein expressed in proliferating cells. Staining with Ki-67 can help assess the proliferative activity of normal and tumor tissues. Dye azide No. 36 (top row) and reference dye CF680R (bottom row) were used for staining at a concentration of 200 μM. Results: Correct cellular structures were stained with no obvious background, demonstrating the compatibility of dye No. 36 with immunohistochemical staining.
[0046] Figure 5 The diagram shows a general reaction scheme for synthesizing the fluorescent dye according to the present invention. Detailed Implementation
[0047] definition
[0048] Unless otherwise specified, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. While substantially any methods and materials similar to those described herein may be used in the practice or testing of this invention, only exemplary methods and materials are described. For the purposes of this invention, the following terms are defined as follows.
[0049] Unless the context clearly indicates otherwise, the terms “a,” “an,” and “the” include plural references.
[0050] As used herein and unless otherwise stated, the term "alkyl" refers to a saturated, monovalent, straight-chain or branched hydrocarbon chain. Examples of alkyl groups include, but are not limited to, C1-C6 alkyl groups such as methyl, ethyl, propyl, isopropyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 2-methyl-1-butyl, 3-methyl-1-butyl, 2-methyl-3-butyl, 2,2-dimethyl-1-propyl, 2-methyl-1-pentyl, 3-methyl-1-pentyl, 4-methyl-1-pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-1-butyl, 3,3-dimethyl-1-butyl, 2-ethyl-1-butyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl, neopentyl and hexyl, as well as longer alkyl groups such as heptyl and octyl. The alkyl group can be unsubstituted or substituted with one or two suitable substituents.
[0051] As used herein and unless otherwise stated, the chemical symbols “Si” and “Ge” refer to silicon and germanium, respectively. Furthermore, as used herein, “Me” refers to methyl, “Et” to ethyl, “iPr” to isopropyl, and “Ph” to phenyl.
[0052] As used herein and unless otherwise stated, the term -O-alkyl (or alkyl-O-) means "alkoxy group," where the alkyl group is as defined above. The alkoxy group may be unsubstituted or substituted with one or more suitable substituents. The alkyl chain of the alkoxy group may be, for example, 1 to 6 carbon atoms long.
[0053] As used herein and unless otherwise stated, the term "metal" refers to Group I or Group II metals, including but not limited to Li. + Na + Ca 2+ or Mg 2+ .
[0054] As used herein and unless otherwise stated, the terms “linking group” and “linker” are used interchangeably and refer to a portion of a detectable label capable of covalently binding a base to the label, for example, forming a “link” that connects a nucleoside, nucleotide, or nucleic acid to the label. Examples of linkers include, but are not limited to, O, S, or NH. Optionally, the linking group or linker is a covalent bond (i.e., the label is covalently bound to a base).
[0055] As used herein and unless otherwise stated, the term "anti-charged ion" refers to a stable and synthetically obtainable ion. Examples of anti-charged ions include, but are not limited to, chloride, bromide, iodide, sulfate, benzenesulfonate, p-toluenesulfonate, p-bromobenzenesulfonate, methanesulfonate, trifluoromethanesulfonate, phosphate, perchlorate, tetrafluoroborate, hexafluorophosphate, tetraphenylboronide, nitrate, and anions of aromatic or aliphatic formic acids.
[0056] The terms “click chemistry,” “click reaction,” and “click chemical reaction” are used interchangeably and refer to the [3+2] cycloaddition reaction between alkynes and azides, which exhibits significant selectivity in conjugation reactions in biological samples, as first described by Rostovtsev et al., Angew. Chem. Int. Ed., 2002, 41, 2596-2599, which is incorporated herein by reference in its entirety. Although early click chemistry reactions utilized copper as a catalyst, copper-free click chemistry reactions are preferred in nucleic acid research, and the use of dibenzocyclooctyne (DBCO) derivatives is described in WO2009 / 067663 (which is incorporated herein by reference in its entirety). Reagents such as DBCO-deoxythymidine (DBCO-dT) and DBCO-serine are available as phosphoramidites for oligonucleotide synthesis from Glen Research (Sterling, VA).
[0057] The compounds according to the invention provide molecules that are well-suited as dyes, particularly as fluorescent dyes, due to their spectral properties (maximum absorption in the wavelength region of about 650 nm and higher and maximum emission above 670 nm). Particularly preferred are those exhibiting maximum absorption at about 700 nm. Furthermore, the spectral properties of these molecules can be altered by changing the identity, number, and position of residues relative to Z, W, R1, and R2. In this way, fluorescent dyes exhibiting virtually any maximum absorption and emission above 650 nm can be produced. Therefore, the subject matter of the invention is also the use of the rhodamine derivatives according to the invention as fluorescent dyes or as laser dyes.
[0058] In the compound of general formula A or B according to the invention, at least one of residues R1 or R2 is preferably present in the form of an activated group suitable for coupling or in the form of a group that can be activated for coupling. Such activated groups are particularly derived from activated carboxylic acid or sulfonic acid groups and can be, for example, esters, anhydrides, acyl halides, preferably bromides, especially chlorides, or N-hydroxysuccinimide esters or ω-alkyl halides. Furthermore, such activated groups can also be, for example, phosphoramides.
[0059] To produce conjugates comprising the rhodamine derivatives according to the present invention, activated derivatives suitable for biomolecular labeling or labeling other analytical reagents can be synthesized. The production of activated derivatives requires at least one activatable group, wherein activation is performed according to standard protocols known to the experts. Different reactive groups may be introduced depending on the subsequent application. Phosphite and H-phosphonate may, for example, be derived from hydroxyl groups. Therefore, the production of rhodamine phosphorite and H-phosphonate is generally performed according to protocols known to date (Methods in Mol. Biol. Vol. 20. "Protocols for Oligonucleotides and Analogs, Synthesis and Properties". S. Agrawal Hrsg., Humana Press Totowa, NJ).
[0060] However, N-hydroxysuccinimide (NHS) esters are typically derived from carboxyl groups, maleimides derived from amino groups (PYReddy, Synthesis (1998) 999), or by formic acid extended with the corresponding ω-aminoalkyl maleimide.
[0061] The production of NHS-esters is preferably carried out according to the method described in EP0543333, wherein free formic acid is mixed with NHS in the presence of a condensing agent such as DCC or MEI. The production of rhodamine isothiocyanate is preferably carried out by reacting an amino group with sulfur phosgene (Advanced Organic Chemistry, McGraw Hill, 2nd ed., p. 383, 1997).
[0062] Therefore, the subject of this invention is also the activated derivatives of rhodamine according to the present invention. The reactive groups of the activated derivatives are preferably phosphoramides, N-hydroxysuccinimide (NHS) esters, maleimide-alkylamides, H-phosphonates, isothiocyanates, or ω-alkyl halides.
[0063] Another subject of this invention is conjugates obtainable by combining a rhodamine compound or an activated derivative thereof according to the invention. Thus, such conjugates consist of at least two components, one of which represents a rhodamine derivative according to the invention. The conjugates are produced according to a standard procedure, starting with the activated derivative. Suitable conjugation methods for application are known to those skilled in the art.
[0064] Once the second component of the conjugate can bind to the binding partner to be analyzed and the constructed complex can be identified by detecting the fluorescence emitted by the constructed complex after light excitation with an appropriate absorption wavelength, the conjugate according to the present invention can be used for analytical purposes.
[0065] Due to absorption in the near-infrared region, the compounds according to the present invention are also suitable for in vivo use. For this purpose, water-soluble derivatives of the dyes according to the present invention and their conjugates are administered together with biomolecules. In vivo measurements are performed by measuring fluorescence or absorption.
[0066] The uses of the conjugates described according to the present invention are particularly applicable to diagnostic analysis or the analysis of medical or biological materials. Therefore, the subject matter of the present invention is particularly those conjugates capable of interacting with biomolecules. These conjugates typically also contain one or more biomolecules as further components.
[0067] The biomolecules contained in the conjugate can be, for example, single-stranded or double-stranded nucleic acids, such as DNA, RNA, or triple-helix structures, or nucleic acid analogs such as PNA, oligonucleotides, and oligonucleotide derivatives, or mononucleotides, nucleotide derivatives, nucleotide analogs, or nucleoside triphosphates. Labeling of such molecules occurs at the 5′ position (preferably via NHS esters or phosphorous acid) and at the 3′ position (but preferably via dye-substituted carrier substances such as CPG). Labeling at other positions, such as nucleic acid bases, is also preferably via NHS esters.
[0068] When labeling proteins, protein complexes, antibodies, or amino acids, conjugation is preferably performed via NHS esters, m-maleimides, isothiocyanates, or ω-alkyl halides. Examples of other conjugation components include vitamins, steroid hormones, lipid molecules, and haptens. Furthermore, more complex biological structures, such as membrane portions or entire cells, can be labeled.
[0069] A specific embodiment of the conjugate according to the invention is an oligonucleotide conjugated with a rhodamine derivative according to the invention. Oligonucleotides labeled in this manner can be used in known nucleic acid detection and analysis methods, such as by in situ hybridization (Meyne and Myzis, Methods Mol. Biol. 33. 63-74, 1994), or as primers in various sequencing methods (Sheealy et al., Anal. Chem. 67. 247-251, 1995).
[0070] In addition to chemical labeling of nucleic acids, ribonucleoside triphosphates and deoxyribonucleoside triphosphates labeled with rhodamine dye according to the present invention can also be inserted into nucleic acids as substrates for polymerases via different enzymatic reactions. For DNA, this is achieved by DNA polymerases, for example by applying a nick translation method (Rigby et al., J. Mol. Biol. 113, p. 237, 1977) or by “random primer labeling” (Feinberg and Vogelstein. Anal. Biochem. 137, p. 266, 1984). In the case of RNA, this is achieved, for example, by using T3, T7, or SP6 RNA polymerases. Another nucleic acid labeling method can be achieved by using a so-called 3′-tailing reaction of terminal transferases.
[0071] Therefore, another subject of the present invention is the use of the conjugates according to the present invention for labeling nucleic acids by chemical or enzymatic methods, and the use of the labeled hybridization probes according to the present invention for detecting and analyzing nucleic acids.
[0072] For analytical determination, the rhodamine derivative according to the invention is first excited with light of an appropriate wavelength, such as a laser, laser diode, or LED. Depending on the analyte, fluorescence detection is performed using measurement methods known to experts. These methods include, for example, fluorescence microscopy for in-situ methods or detection of emitted radiation by a suitable photodiode.
[0073] Therefore, another subject of the present invention is the use of dye conjugates for immunohistochemical staining of paraffin tissue sections. Immunohistochemistry allows for the visualization of antigens via the sequential application of a specific antibody (primary antibody) bound to the antigen, a secondary antibody (conjugating antibody) bound to the primary antibody, an enzyme complex, and a chromogenic substrate followed by an insertion and washing step. Enzymatic activation of the chromophore results in the production of visible reaction products at the antigen site.
[0074] In addition to directly exciting the dye according to the invention using radiation energy of a suitable wavelength, excitation can also be achieved through so-called fluorescence resonance energy transfer (also known as fluorescence resonance energy transfer). This is achieved through resonance energy transfer. Utilizing this principle, a second fluorescent dye is excited by light of an appropriate wavelength. Due to the local proximity of the two dyes, a nonradiative energy transfer subsequently occurs to the rhodamine derivative according to the invention (Vander Meer et al., Resonance Energy Transfer, VCH, 1994). Detection of the light emitted by the molecule at a specific wavelength can preferably be used for the quantitative determination of the analyte. Therefore, one subject of the invention is also the use of the rhodamine derivative or corresponding conjugate according to the invention as a component of a fluorescence resonance energy transfer system.
[0075] The compounds according to the present invention are used as resonance energy donors or acceptors. Preferred resonance energy donors for all compounds according to the present invention are fluorescent dye conjugates suitable for spectroscopic analysis. Therefore, one subject of the present invention is also the use of rhodamine derivatives or corresponding conjugates according to the present invention, together with suitable fluorescent resonance donor conjugates, as fluorescent resonance energy acceptors in fluorescence resonance energy transfer systems.
[0076] For the quantitative detection of nucleic acids, hybridization probes labeled with fluorescent dyes, such as oligonucleotides, are suitable, as they can be detected using the principle of fluorescence resonance electron transfer (FRET). In the case of oligonucleotides, the 5′ end can be labeled, for example, with one dye component of the FRET system, while the 3′ end can be labeled with the remaining dye component of the FRET system. In this case, the oligonucleotide can also be labeled intra-sequence.
[0077] In one particular embodiment, such oligonucleotides labeled with two dyes are used during nucleic acid amplification to detect the resulting product, wherein emission of the fluorescence resonance energy donor is determined. If the oligonucleotide does not bind to the target, donor fluorescence cannot be measured due to nonradiative energy transfer. However, if the oligonucleotide binds to the target DNA, the two dye components are locally separated due to the exonuclease activity of the DNA polymerase used, making the specific fluorescence level of the FRET donor measurable (US Patent No. 5,210,015).
[0078] In other preferred embodiments, different dyes are located on two different hybridization probes that can hybridize in a localized region adjacent to the target nucleic acid. These probes can be, for example, two oligonucleotide probes that hybridize to the same strand of the target nucleic acid, with one dye located at the 3′ end of the first probe and the other at the 5′ end of the second probe, such that the distance between them consists of only a small number of nucleotides (i.e., numbers between 0 and 30). When using fluorescein in combination with rhodamine derivatives according to the invention, distances of 0 to 15 nucleotides, particularly 1 to 5 nucleotides, and in many cases only one nucleotide, have proven advantageous. If the nucleotide distance between the dye components remains constant, the probe is not conjugated to the dye at the end, but can still be used internally. In the case of double-stranded target nucleic acids, probes binding to different strands of the target can also be used, provided that there is a specific nucleotide distance of 0 to 30 nucleotides between the two dye components.
[0079] Therefore, another subject of the invention is the use of conjugates according to the invention, consisting of oligonucleotides and rhodamine derivatives, for the analysis of nucleic acids, wherein a further conjugate consisting of a second oligonucleotide and another suitable fluorescent dye is used, and wherein fluorescence resonance energy transfer (FRET) occurs upon excitation of a dye preferably coupled to the second oligonucleotide. The oligonucleotide combination is referred to hereinafter as a “FRET pair” and is thus labeled.
[0080] It has been shown that the use of such FRETs during or after polymerase chain reaction is particularly advantageous for detecting amplification products. Therefore, another subject of the invention is the use of the conjugates described according to the invention as components of FRET pairs for detecting reaction products of nucleic acid amplification reactions. In a particular detection procedure, one of the two amplification primers can be simultaneously labeled with one of two dyes, thereby providing one of the two components of the FRET.
[0081] Using appropriate FRET pairs to detect amplification products allows for so-called "real-time monitoring" of the PCR reaction, determining the data required to generate amplification products based on the number of reaction cycles initiated. This is typically achieved by the fact that the oligonucleotides of the FRET pair also hybridize with the target nucleic acid due to the reaction and temperature conditions during the annealing of the amplification primers, and emit a measurable fluorescence signal upon appropriate excitation. Using the obtained data, the amount of target nucleic acid initially applied can be determined by quantitative analysis. Therefore, these examples are particularly important for quantitative RT-PCR experiments for the quantitative analysis of RNA concentration in biological samples. Thus, one subject of the invention is also the use of the conjugates described according to the invention as components of FRET pairs for detecting reaction products in nucleic acid amplification reactions, wherein the reaction products are detected in each cycle. Furthermore, another subject of the invention is the use of the conjugates described according to the invention as components of FRET pairs for the quantitative determination of nucleic acids to be amplified.
[0082] In different embodiments, after the FRET pair hybridizes with the target nucleic acid to be detected, the amplification product is detected after the amplification reaction is completed, as the temperature continues to rise during fusion curve analysis. Simultaneously, the emitted fluorescence, which depends on the temperature, is measured. This allows the detection of sequences that do not hybridize tightly with the FRET pair used due to specific mismatches. The fusion point determined in this way can be used to detect point mutations or other polymorphisms. Therefore, one subject of the invention is also the use of the conjugates described according to the invention as components of FRET pairs for determining fusion curves (particularly during the identification of polymorphisms and point mutations).
[0083] Such fluorescence resonance energy transfer processes are often used to determine molecular-molecule interactions, such as protein-protein interactions or antigen-antibody reactions. Specific advantages are gained when the reaction is carried out under homogeneous conditions.
[0084] As the anti-charge ion, various cations suitable for charge neutralization and compatible with the basic anionic structure of the present invention according to pH can be used.
[0085] The starting compound is preferably selected in such a way that the synthesized product contains a group suitable for activation. This group is activated according to known methods to obtain a group suitable for subsequent coupling with a reactive group of a bioactive molecule to construct a biomolecule-dye conjugate. A linker may be inserted between the activated group and the bioactive molecule.
[0086] The linker is used to alter the distance between the dye and the biomolecule according to the invention. For extended purposes, chlorohexanoic acid can be inserted into formic acid, for example. This may also involve changes in functional groups, for example, through the reaction of formic acid with maleimide alkylamines. Furthermore, the linker charge can affect the solubility of the dye. Amino acids carrying charge carriers, such as lysine or glutamic acid, are particularly well-suited for this effect.
[0087] With the aid of the compounds described in this invention, novel compounds are provided that are well-suited as absorbent dyes for coupling, particularly as fluorescent dyes for haptens, antibodies, and protein conjugated contaminants, due to their spectral properties (maximum absorption above 650 nm), and are also well-suited for polynucleotide labeling and latex staining (fluorescent latex).
[0088] If the rhodamine derivative dyes according to the present invention are soluble in water-immiscible organic solvents and can be inserted into latex through a swelling process, they are particularly suitable for insertion into latex. Such fluorescent latexes with diameters ranging from about 50 nm to at most several μm can be loaded by various coating methods, such as loading with proteins, haptens, or nucleic acids.
[0089] The mixture is dyed with at least one dye according to the present invention, such that resonant energy transfer can occur.
[0090] Conjugates of fluorescent dyes with haptens (such as, for example, theophylline, digoxin, T3, T4) or proteins (such as antibodies) are suitable for diagnostic systems, particularly for fluorescence immunoassays and fluorescence polarization immunoassays.
[0091] Another subject of the invention is a procedure for determining a first immunolinkable substance, wherein a conjugate of the compound according to the invention is used in conjunction with a second (immuno)linkable substance, which may be similar to or different from the first substance, and the absorption change, fluorescence change, or fluorescence-polarization change of the compound according to the invention caused by a (immunological) binding reaction specific to the first substance is determined as an indicator of the content of the analyte and contained substance in the sample.
[0092] Another subject of the present invention is the use of the conjugates according to the invention in immunoassays.
[0093] As used in this article, "biocompatible" substances are non-toxic and have no substantial harmful effects on biomolecules.
[0094] As used herein and unless otherwise stated, the term "nucleobase" refers to adenine, cytosine, guanine, thymine, or uracil.
[0095] As used herein and unless otherwise stated, the term "nucleobase analog" refers to a substituted or unsubstituted nitrogen-containing parent heteroaromatic ring capable of forming Watson-Crick hydrogen bonds with complementary nucleobases or nucleobase analogs. Preferably, the nucleobase analog is a purine, deazopurine, or pyrimidine. Exemplary nucleobase analogs include, but are not limited to, 7-deazopurine, inosine, nebularine, nitropyrrole, nitroindole, 2-aminopurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, 5-propynylcytidine, isocytidine, isoguanine, 7-deazoguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiothymidine, 4-thiouracil, and O. 6 -Methylguanine, N 6 -Methyladenine, O 4 -Methylthymidine, 5,6-dihydrothymidine, 5,6-dihydrouracil, 4-methylindole, ethynyl adenine, etc. Other exemplary nucleobase analogs can be found in Fasman, 1989, Practical Handbook of Biochemistry and Molecular Biology, pp. 385-394, CRC Press, Boca Raton, FL, and the references cited therein, which are incorporated herein by reference.
[0096] As used herein and unless otherwise stated, the term "nucleoside" refers to a compound consisting of a nucleobase covalently linked to the C1′ carbon of a substituted or unsubstituted ribose. Typical substituted ribose include, but are not limited to, those in which one or more carbon atoms, preferably one, most preferably the 3′ carbon atom, are substituted by one or more identical or different -R, -OR, -NRR, or halogen groups, wherein each R is independently -H, (C1-C6)alkyl, or (C5-C6)alkyl. 14 Aryl group. Particularly preferred ribose sugars include ribose, 2′-deoxyribose, 2′,3′-deoxyribose, 3′-haloribose, 3′-fluororibose, 3′-chlororibose, and 3′-alkylribose. When the nucleobase is A or G, the ribose is attached to the N-terminus of the nucleobase. 9 Position. When the nucleobase is C, T, or U, the pentose is attached to the N of the nucleobase. 1 Location (see, for example, Kornberg and Baker, 1992, DNA Replication, 2nd ed., Freeman, San Francisco).
[0097] As used herein and unless otherwise stated, the term "nucleoside analog" refers to a nucleoside in which a nucleobase, ribose, or both are substituted by their respective analogs. Exemplary nucleobase analogs are those previously defined. Exemplary ribose analogs include, but are not limited to, substituted or unsubstituted furanoses (e.g., erythrose and hexoses) having more or fewer five ring atoms, and substituted or unsubstituted acyclic sugars with 3-6 carbons. Typical substituted furanoses and acyclic sugars are those in which one or more carbon atoms are substituted by one or more of the same or different -R, -OR, NRR, or halogen groups, wherein each R is independently H, (C1-C6) alkyl, or (C5-C6) alkyl. 14 Aryl.
[0098] As used herein and unless otherwise stated, the term "nucleotide" refers to a nucleoside in which one or more (usually one) ribose carbons are replaced by a phosphate ester having the following formula:
[0099]
[0100] Where a is an integer between 0 and 4. Preferably, a is 2 and the phosphate ester is attached to the 3′ or 5′ carbon of the ribose, for example, ribose 3′-triphosphate, 2′-deoxyribose 3′-triphosphate, ribose 5′-triphosphate, 2′-deoxyribose 5′-triphosphate, 3′-haloribose 5′-triphosphate, 3′-alkylribose 5′-triphosphate, 2′,3′-dideoxyribose 5′-triphosphate, etc.
[0101] As used herein and unless otherwise stated, the term "nucleotide derivative" refers to a nucleotide in which the nucleotide, ribose, and / or one or more phosphate esters are substituted with their respective analogs. Exemplary nucleobase and ribose analogs are those previously described as conjugated with nucleoside analogs. Exemplary phosphate ester analogs include, but are not limited to, alkylphosphonates, methylphosphonates, aminophosphates, triphosphates, thiophosphates, dithiophosphates, linoleic phosphates, diselenophosphates, phosphophenylaminothioates, phosphoaniline esters, phosphocarbamates, borate phosphates, peptide nucleic acid (PNA) monomers, etc., including any associated anti-loading agent (if present).
[0102] As used herein and unless otherwise stated, the term "protecting group" means a group that is reversibly attached to a hydroxyl or amine moiety such that the hydroxyl or amine moiety does not react in subsequent reactions and can be selectively cleaved to regenerate the hydroxyl or amine moiety once protection is achieved. Examples of protecting groups can be found in Greene, TW, Protective Groups in Organic Synthesis, 3rd edition (1999), which is incorporated herein by reference. In one embodiment, the protecting group is stable in an alkaline reaction medium but can be cleaved by acid. Examples of base-stable and acid-unstable protecting groups suitable for use in this invention include, but are not limited to, ethers such as methyl, methoxymethyl, methylthiomethyl, methoxyethoxymethyl, bis(2-chloroethoxy)methyl, tetrahydropyranyl, tetrahydrothiaranyl, tetrahydrofuranyl, tetrahydrothiofuranyl, 1-ethoxyethyl, 1-methyl-1-methoxyethyl, tert-butyl, allyl, benzyl, o-nitrobenzyl, triphenylmethyl, α-naphthyldiphenylmethyl, p-methoxyphenyl-diphenylmethyl, 9-(9-phenyl-10-oxo)anthrayl, trimethylsilyl, isopropyldimethylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, tribenzylsilyl and triisopropylsilyl; and esters such as neopentanoate, adamantanoate and 2,4,6-trimethylbenzoate.
[0103] As used herein and unless otherwise stated, the term "salt" includes, but is not limited to, salts of acidic or basic groups that may be present in the compounds of the present invention. Compounds that are inherently basic are capable of forming a variety of salts with a wide range of inorganic and organic acids. Acceptable acid addition salts that can be used to prepare such basic compounds are those acids that form non-toxic acid addition salts, i.e., salts containing pharmaceutical anions, including but not limited to sulfuric acid, citric acid, maleic acid, acetic acid, oxalic acid, hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, hydrogen sulfate, phosphate, acid phosphate, isonicotinate, acetate, lactic acid, salicylate, citrate, acid citrate, tartrate, oleate, tannate, pantothenate, hydrogen tartrate, ascorbate, succinate, maleate, gentianate, fumarate, gluconate, glucuronide, sucrose, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, and bis(hydroxynaphthyl)ate (i.e., 1,1′-methylene-bis(2-hydroxy-3-naphthylcarbamate)). In addition to the acids mentioned above, compounds of the present invention including the amino moiety can also form acceptable salts with various amino acids. The compounds of this invention, which are inherently acidic, are capable of forming alkaline salts with a variety of pharmaceutical cations. Examples of such salts include alkali metal salts or alkaline earth metal salts, and in particular calcium, magnesium, sodium, lithium, zinc, potassium, and iron salts.
[0104] As used herein and unless otherwise stated, the term "solvent" means a compound of the present invention or a salt thereof, further comprising a stoichiometric or non-stoichiometric solvent bound by non-covalent intermolecular forces. Preferred solvents are volatile and non-toxic. The term "solvent" includes hydrates. "Hydrate" means a compound of the present invention or a salt thereof, further comprising a stoichiometric or non-stoichiometric water bound by non-covalent intermolecular forces.
[0105] As used herein and unless otherwise stated, the term "nucleoside or nucleotide" means nucleosides and / or nucleotides and / or mixtures thereof.
[0106] The term "nucleoside analog" refers to a nucleoside in which a nucleobase, ribose, or both are substituted by their respective analogs. Exemplary nucleobase analogs are those previously defined. Exemplary ribose analogs include, but are not limited to, substituted or unsubstituted furanoses (e.g., erythrose and hexoses) having more or fewer five ring atoms, and substituted or unsubstituted acyclic sugars with 3-6 carbons. Typical substituted furanoses and acyclic sugars are those in which one or more carbon atoms are substituted by one or more of the same or different -R, -OR, NRR, or halogen groups, wherein each R is independently H, C1-C6 alkyl, or C5-C6 alkyl. 14 Aryl.
[0107] As used herein and unless otherwise stated, the term "nucleotide analog" refers to a nucleotide in which the nucleotide, ribose, and / or one or more phosphate esters are substituted with their respective analogs. Exemplary nucleobase and ribose analogs are those previously described that are conjugated with nucleoside analogs. Exemplary phosphate ester analogs include, but are not limited to, alkylphosphonates, methylphosphonates, aminophosphates, triphosphates, thiophosphates, dithiophosphates, linoleic phosphates, diselenophosphates, phosphophenylaminothioates, phosphoaniline esters, phosphocarbamates, borate phosphates, peptide nucleic acid (PNA) monomers, etc., including any associated anti-loading agent (if present).
[0108] As used herein and unless otherwise stated, the term "nucleic acid" refers to a linear polymer chain of nucleoside monomer units covalently linked to each other by phosphate ester nucleotide bonds. Unless otherwise stated, "nucleic acid" as used herein includes polymers of any length, including oligonucleotides, nucleic acids, and nucleic acids as commonly used in the art. Therefore, the size range of nucleic acids according to the invention can be from a few monomer units (e.g., 4 to 40), to hundreds, thousands, or even more monomer units. Such nucleic acids may also be described herein in terms of their function, such as primers or probes. Whenever a nucleic acid is represented by a letter sequence such as "ATGCCTG," it should be understood that the sequence is presented in a 5′→3′ orientation. Unless otherwise stated, the nucleic acids of the sequences described herein are 2′-deoxyribonucleic acid (DNA).
[0109] As used herein and unless otherwise stated, the term "nucleic acid analog" refers to a nucleic acid in which at least one nucleoside monomer unit is a "nucleoside analog" and / or at least one phosphate ester nucleotide internucleotide bond is a phosphate ester analog, as defined above in "nucleotide analogs". Preferred categories of nucleic acid analogs are those in which the sugar and nucleotide internucleotide bonds are replaced by uncharged neutral amides, such as carbamoyl morpholino and peptide nucleic acids ("PNA"). Preferred PNAs are those having an N-(2-aminoethyl)glycine amide backbone (see, for example, Nielsen et al., 1991, Science 254: 1497-1500).
[0110] As used herein and unless otherwise stated, the term "marker" refers to a detectable molecule or atom covalently or non-covalently attached to a nucleoside or nucleotide, nucleoside or nucleotide analog, nucleic acid, nucleic acid analog, or terminator. In one embodiment, the nucleoside or nucleotide, nucleoside or nucleotide analog, nucleic acid, nucleic acid analog, or terminator has a detectable marker covalently attached to a nucleobase. The term "marker" can also refer to a molecule that modulates the detection of another detectable marker (such as a quencher). As used herein, the term "detectable marker" is intended to include not only molecules or markers that are "directly" detected (e.g., chromophores or fluorophores) but also portions that are "indirectly" detected (e.g., biotin) by binding to a second, third, or higher binding partner (e.g., avidin or streptavidin), one of which carries a "direct" marker.
[0111] Other examples of labels include fluorescent compounds that become detectable due to fluorescence when exposed to light of an appropriate wavelength, and can be detected and / or measured by microscopy or fluorescence methods. Commonly used fluorescent labeling compounds include fluorescein isothiocyanate, rhodamine, phycoerythrin, phycocyanin, allophycocyanin, gamma-benzaldehyde, and fluorescein. Detectable labels can also be fluorescent metals, such as… 152Eu, or other metals of the lanthanide elements, can be attached to oligonucleotides using metal chelating groups, such as diethylenetriaminepentaacetic acid or ethylenediaminetetraacetic acid.
[0112] The label can be a chemiluminescent compound, the presence of which is detected by measuring the light emitted during a chemical reaction. Examples of useful chemiluminescent labeling compounds are luminol, isoluminol, theromaticacridinium ester, imidazole, acridine salts, and oxalates. Similarly, bioluminescent compounds can be used to label oligonucleotides and detected by measuring their light emission. In this case, catalytic proteins enhance the efficiency of the chemiluminescent reaction. Examples of available bioluminescent labeling compounds include luciferin, luciferase, and jellyfish luminescent protein.
[0113] As used herein and unless otherwise stated, the term "reporter dye" refers to a compound that emits energy in the form of fluorescence when exposed to light. The "chromophore of a reporter dye" is a network of atoms of the reporter dye that emit radiation levels detectable by conventional spectroscopic methods when exposed to light.
[0114] As used herein and unless otherwise stated, the term "non-fluorescent" refers to a compound that emits radiation at a level that is not detectable by conventional spectroscopic means when exposed to radiation.
[0115] As used herein and unless otherwise stated, the term “weak fluorescence” refers to a compound that emits low levels of radiation detectable by conventional spectroscopic means when exposed to radiation.
[0116] As used herein and unless otherwise stated, the term “light” means electromagnetic energy having a wavelength that causes the reporter dye to fluoresce, wherein the wavelength may be in the range of 190–800 nm.
[0117] As used herein and unless otherwise stated, the term "specificity" means that the nucleic acids used in the reaction, such as probes used in hybridization reactions, primers used in PCR, or nucleic acids present in the composition, hybridize only with the intended target and not with other nucleic acid molecules in the sample being tested, under normal detection conditions.
[0118] As used herein and unless otherwise stated, the term “selectivity” means that the nucleic acids used in a reaction, such as probes used in a hybridization reaction, primers used in PCR, or nucleic acids present in a pharmaceutical preparation, hybridize with the target at a higher frequency, faster, or longer duration than hybridization with other nucleic acids in the test sample in a normal testing environment.
[0119] As used herein, the term "hybridization under stringent conditions" describes the conditions under which hybridization and washing typically preserve nucleotide sequences that are at least 60% (65%, 70%, or 75% or higher) identical to each other. The stringent conditions depend on the nature of the nucleic acids (e.g., length, GC content, etc.) and the method itself (hybridization, amplification, etc.). Such methods are well known in the art, see Current Protocols in Molecular Biology, John Wiley & Sons, NY (1989), 6.3.1–6.3.6. In one embodiment, stringent hybridization conditions involve hybridization at approximately 45°C in 6X sodium chloride / sodium citrate (SSC), followed by washing once or multiple times at approximately 68°C in 0.1X SSC, 0.2% SDS. In another embodiment, the stringent hybridization conditions are hybridization at approximately 45°C in 6X SSC, followed by washing once or multiple times at 50-65°C in 0.2X SSC, 0.1% SDS (i.e., washing once or multiple times at 50°C, 55°C, 60°C, or 65°C). It should be understood that the nucleic acids of the present invention do not include nucleic acid molecules that hybridize only to nucleotide sequences consisting solely of A or T nucleotides under these conditions. For example, oligonucleotides of approximately 15-40 bases can be stringently hybridized to complementary sequences in polymerase chain reaction (PCR) under the following conditions: a salt concentration of 50 mM KCl, a buffer concentration of 10 mM Tris HCl, and Mg... 2+ The concentration is 1.5 mM, pH is 7-7.5, and annealing temperature is 55-60℃. Moderately strict hybridization of approximately 15-40 base oligonucleotides to complementary sequences in polymerase chain reaction (PCR) can be performed under the following conditions: salt concentration of 50 mM KCl, buffer concentration of 10 mM Tris HCl, and Mg... 2+ The concentration is 1.5 mM, pH is 7-7.5, and annealing temperature is 48-54℃. Low-strict hybridization of approximately 15-40 base oligonucleotides to complementary sequences in polymerase chain reaction (PCR) can be performed under the following conditions: salt concentration of 50 mM KCl, buffer concentration of 10 mM Tris·HCl, and Mg... 2+ The concentration is 1.5 mM, the pH is 7-7.5, and the annealing temperature is 37-47℃.
[0120] As used herein and unless otherwise stated, the term "stereoisopure" refers to a composition comprising one stereoisomer of a compound and substantially free of other stereoisomers of that compound. For example, a stereoisopure composition of a compound having one chiral center will substantially free of the opposite enantiomers of that compound. A stereoisopure composition of a compound having two chiral centers will substantially free of other diastereomers of that compound. Typical stereoisopure compounds comprise more than about 80% by weight of one stereoisomer of the compound and less than about 20% by weight of other stereoisomers of the compound, more preferably more than about 90% by weight of one stereoisomer of the compound and less than about 10% by weight of other stereoisomers of the compound, even more preferably more than about 95% by weight of one stereoisomer of the compound and less than about 5% by weight of other stereoisomers of the compound, and most preferably more than about 97% by weight of one stereoisomer of the compound and less than about 3% by weight of other stereoisomers of the compound.
[0121] As used herein and unless otherwise stated, the term "substantially free" means a composition that contains one compound and is free of detectable or substantial amounts of other compounds. A typical substantially free composition contains more than about 80% by weight of the target compound and less than about 20% by weight of one or more other compounds, more preferably more than about 90% by weight of the target compound and less than about 10% by weight of one or more other compounds, even more preferably more than about 95% by weight of the target compound and less than about 5% by weight of one or more other compounds, and most preferably more than about 97% by weight of the target compound and less than about 3% by weight of one or more other compounds.
[0122] The method for nucleic acid amplification is polymerase chain reaction (PCR), disclosed in U.S. Patent Nos. 4,683,202, 4,683,195, 4,800,159, and 4,965,188, as well as other references. PCR typically employs two or more oligonucleotide primers that bind to a selected nucleic acid template (e.g., DNA or RNA). Primers used for nucleic acid analysis comprise oligonucleotides capable of acting as initiation sites for nucleic acid synthesis within the nucleic acid sequence of the target nucleic acid. Primers can be purified from restriction digests using conventional methods or can be synthesized synthetically. For maximum efficiency in amplification, primers can be single-stranded, but primers can also be double-stranded. Double-stranded primers are first denatured (i.e., treated) to separate the strands. One method for denaturing double-stranded nucleic acids is by heating. A "thermostable polymerase" is a thermostable polymerase, meaning it is an enzyme that catalyzes the formation of primer extension products complementary to the template and does not undergo irreversible denaturation when subjected to elevated temperatures for the time required to denature the double-stranded template nucleic acid. Generally, synthesis begins at the 3′ end of each primer and proceeds along the template strand in the 5′ to 3′ direction. Thermostable polymerases have been isolated from, for example, *Thermus flavus*, *T. ruber*, *T. thermophilus*, *T. aquaticus*, *T. lacteus*, *T. rubens*, *Bacillus stearothermophilus*, and *Methanothermus fervidus*. However, thermostable polymerases can also be used in PCR assays, provided that the enzyme is supplemented.
[0123] If the template nucleic acid is double-stranded, both strands must be separated before it can be used as a template in PCR. Strand separation can be accomplished by any suitable denaturation method, including physical, chemical, or enzymatic methods. One method for separating nucleic acid strands involves heating the nucleic acid until it is mostly denatured (e.g., greater than 50%, 60%, 70%, 80%, 90%, or 95% denatured). The heating conditions necessary to denature the template nucleic acid will depend, for example, the buffer salt concentration and the length and nucleotide composition of the denatured nucleic acid, but are generally in the range of about 90°C to about 105°C, lasting for a period of time depending on reaction characteristics such as temperature and nucleic acid length. Denaturation typically takes about 5 seconds to 9 minutes. To avoid exposing the corresponding polymerase (e.g., Z05 DNA polymerase) to such high temperatures for too long and thus risking loss of functional enzyme activity, a short denaturation step is preferred.
[0124] If the double-stranded template nucleic acid is denatured by heating, the reaction mixture is allowed to cool to a temperature that promotes the annealing of each primer to its target sequence on the target nucleic acid.
[0125] The annealing temperature can be from about 35°C to about 70°C, or from about 45°C to about 65°C; or from about 50°C to about 60°C, or from about 55°C to about 58°C. The annealing time can be from about 10 seconds to about 1 minute (e.g., from about 20 seconds to about 50 seconds; from about 30 seconds to about 40 seconds). In this context, it can be advantageous to use different annealing temperatures to increase the inclusiveness of the corresponding assays. In short, this means that at relatively low annealing temperatures, primers can also bind to targets with a single mismatch, and therefore variants of certain sequences can also be amplified. This is also desirable if, for example, an organism has a known or unknown genetic variant (which should also be detected). On the other hand, relatively high annealing temperatures have the advantage of providing higher specificity, because the probability of primers binding to imperfectly matched target sequences decreases progressively with increasing temperatures. To benefit from both phenomena, in some embodiments of the invention, the above-described method includes annealing at different temperatures, for example, first annealing at a lower temperature and then annealing at a higher temperature. If, for example, the first incubation is performed at 55°C for about 5 cycles, non-exactly matching target sequences can be (pre-)amplified. This can then be followed by, for example, about 45 cycles at 58°C, providing higher specificity for the main part of the experiment. In this way, potentially important genetic variants are not lost, while maintaining relatively high specificity.
[0126] The reaction mixture is then adjusted to a temperature at which polymerase activity is promoted or optimized, sufficient to allow extension from the annealing primers to produce a product complementary to the nucleic acid to be analyzed. The temperature should be sufficient to synthesize an extension product from each primer annealed to the nucleic acid template, but not so high as to denature the extension product from its complementary template (e.g., temperatures used for extension typically range from about 40°C to 80°C (e.g., about 50°C to about 70°C; about 65°C)). Extension times can be about 10 seconds to about 5 minutes, or about 15 seconds to 2 minutes, or about 20 seconds to about 1 minute, or about 25 seconds to about 35 seconds. The newly synthesized chain forms a double-stranded molecule that can be used in later steps of the reaction. The chain separation, annealing, and extension steps can be repeated multiple times as needed to produce the desired amount of amplified product corresponding to the target nucleic acid. The limiting factors in the reaction are the amounts of primers, thermostable enzymes, and nucleosides triphosphates present in the reaction. The cycling steps (i.e., denaturation, annealing, and extension) can be repeated at least once. For use in an assay, the number of cycling steps will depend, for example, on the nature of the sample. If the sample is a complex mixture of nucleic acids, more cycling steps will be needed to amplify a sufficient number of target sequences for detection. Typically, the cycling steps are repeated at least about 20 times, but can be repeated up to 40, 60, or even 100 times.
[0127] PCR can be performed where annealing and extension are carried out in the same step (one-step PCR), or, as described above, in separate steps (two-step PCR). Performing annealing and extension together, and therefore under the same physical and chemical conditions, with suitable enzymes (such as, for example, Z05 DNA polymerase), has the advantage of saving time on additional steps in each cycle and also eliminating the need for additional temperature regulation between annealing and extension. Thus, one-step PCR reduces the overall complexity of the corresponding assay.
[0128] Generally, a shorter overall amplification time may be preferred because it reduces the time to results and leads to possible earlier diagnosis.
[0129] Other nucleic acid amplification methods to be used include ligase chain reaction (LCR; Wu DY and Wallace RB, Genomics 4 (1989) 560-69; and Barany F., Proc. Natl. Acad. Sci. USA 88 (1991) 189-193); polymerase ligase chain reaction (Barany F., PCR Methods and Applic. 1 (1991) 5-16); Gap-LCR (WO90 / 01069); repair chain reaction (EP 0439182 A2), 3SR (Kwoh DY et al., Proc. Natl. Acad. Sci. USA 86 (1989) 1173-1177; Guatelli JC et al., Proc. Natl. Acad. Sci. USA 87 (1990) 1874-1878; WO 92 / 08808), and NASBA (US 5,130,238). In addition, there are strand substitution amplification (SDA), transcription-mediated amplification (TMA) and Qb-amplification (see reviews, e.g., Whelen A.C. and Persing DH, Annu. Rev. Microbiol. 50 (1996) 349-373; Abramson RD and Myers T.W., Curr. Opin. Biotechnol. 4 (1993) 41-47).
[0130] The terms "Cp value," "Ct value," "Ct," or "crossover point" value refer to the values that allow for the quantification of the input target nucleic acid. Cp or Ct values can be determined using the second-derivative maximum method (Van Luu-The et al., "Improved real-time RT-PCR method for high-throughput measurements using second derivative calculation and double correction," BioTechniques, Vol. 38, No. 2, February 2005, pp. 287-293). In the second-derivative method, Cp / Ct corresponds to the first peak of the second-derivative curve. This peak corresponds to the beginning of the logarithmic linear phase. The second-derivative method calculates the second derivative value of the real-time fluorescence intensity curve and obtains only one value. The initial Cp / Ct method is based on a locally defined differentiable approximation of the intensity value, for example, through a polynomial function. The third derivative is then calculated. The Cp / Ct value is the smallest root of the third derivative. Cp / Ct can also be determined using the fitted point method, where Cp / Ct is determined by the intersection of parallel lines and threshold lines in the log-linear region (VanLuu-The et al., BioTechniques, Vol. 38, No. 2, February 2005, pp. 287-293). The LightCycler instrument provided by Roche provides Cp / Ct values by calculation based on the second derivative maximization method.
[0131] The term "PCR efficiency" refers to the cycle-to-cycle amplification efficiency. The PCR efficiency for each condition is calculated using the following equation: PCR efficiency % = (10... (-斜率) -1)×100, where the slope is calculated by linear regression of the log copy number plotted on the y-axis and the Cp plotted on the x-axis. PCR efficiency can be measured using perfectly matched or mismatched primer templates.
[0132] The term "FRET" or "fluorescence resonance energy transfer" or "Fluorescence Resonance Energy Transfer" Resonant energy transfer (FRET) refers to the energy transfer between at least two chromophores, a donor chromophore and an acceptor chromophore (called quenchers). When the donor is excited by light radiation of a suitable wavelength, it typically transfers energy to the acceptor. The acceptor typically re-emits the transferred energy in the form of light radiation of a different wavelength. When the acceptor is a "dark" quencher, it dissipates the transferred energy in a form other than light. Whether a particular fluorophore acts as a donor or acceptor depends on the properties of the other members of the FRET pair. Common donor-acceptor pairs include the FAM-TAMRA pair. Common quenchers are DABCYL and TAMRA. Common dark quenchers include BlackHole Quenchers. TM (BHQ) (Biosearch Technologies, Inc., Novato, Cal.), Iowa Black TM (Integrated DNATech., Inc., Coralville, Iowa) and BlackBerry TM Quencher 650 (BBQ-650) (Berry & Assoc., Dexter, Mich.).
[0133] The method described above can be based on fluorescence resonance energy transfer (FRET) between the donor and acceptor fluorescent fractions. Representative donor fluorescent fractions are fluorescein, and representative corresponding acceptor fluorescent fractions include LC-Red640, LC-Red705, Cy5, and Cy5.5. Typically, detection involves exciting the sample at a wavelength absorbed by the donor fluorescent fraction and displaying and / or measuring the wavelength emitted by the corresponding acceptor fluorescent fraction. In the method according to the invention, FRET can be quantified after detection. For example, detection can be performed after each cycle step. For example, detection can be performed in real time using a commercially available real-time PCR instrument (e.g., LightCycler). TM or Real-time PCR allows for the combination of PCR amplification and detection of amplification products in a single, sealed vial with significantly reduced cycle time. Because detection and amplification occur simultaneously, real-time PCR eliminates the need to manipulate amplification products and reduces the risk of cross-contamination between them. Real-time PCR greatly reduces turnaround time and is an attractive alternative to routine PCR techniques in clinical laboratories.
[0134] The following patent application describes, as The real-time PCRs used in the technology are: WO 97 / 46707, WO97 / 46714 and WO 97 / 46712. The instrument is a rapid thermal cycler combined with a micro-volume fluorometer utilizing high-quality optics. This rapid thermal cycling technology uses thin glass cups as reaction vessels. Heating and cooling of the reaction chamber are controlled by alternating heating with ambient air. Due to the low mass of air and the high surface area to volume ratio of the cups, a very rapid rate of temperature exchange can be achieved within the thermal chamber.
[0135] The technique utilizes a single-stranded hybridization probe labeled with two fluorescent moieties. When the first fluorescent moiety is excited with light of a suitable wavelength, the absorbed energy is transferred to the second fluorescent moiety according to the FRET principle. The second fluorescent moiety is typically a quencher molecule. Typical fluorescent dyes used in this form include, in particular, FAM, HEX, CY5, JA270, Cyan, and CY5.5. During the annealing step of the PCR reaction, the labeled hybridization probe binds to the target nucleic acid (i.e., the amplification product) and is degraded during the subsequent extension phase by the 5′ to 3′ exonuclease activity of Taq or another suitable polymerase known to those skilled in the art (such as a mutant Z05 polymerase). Thus, the excited fluorescent moiety and the quencher moiety become spatially separated from each other. Therefore, fluorescence emission from the first fluorescent moiety can be detected after excitation of the first fluorescent moiety in the absence of a quencher.
[0136] In both of the above detection methods, the intensity of the emitted signal can be correlated with the number of original target nucleic acid molecules.
[0137] Recently, the use of "labeled" [materials / items] has been described in U.S. Patent Publication Nos. 2018 / 0073056 and 2018 / 0073064. The two patents concerning methods for multiplex PCR assays using probes are both incorporated herein by reference in their entirety.
[0138] As a replacement for FRET, double-stranded DNA binding dyes such as fluorescent DNA binding dyes (e.g., SYBRGREEN) are used. or Molecular Probes (MPPs) can detect amplification products. These fluorescent DNA-binding dyes emit a fluorescent signal upon excitation with light of an appropriate wavelength when interacting with double-stranded nucleic acids. Double-stranded DNA-binding dyes, such as nucleic acid intercalation dyes, can also be used. When using double-stranded DNA-binding dyes, melting curve analysis is typically performed to confirm the presence of amplification products.
[0139] Molecular beacons conjugated with FRET can also be used to detect the presence of amplification products using real-time PCR methods according to this disclosure. Molecular beacon technology uses hybridization probes labeled with a first fluorescent moiety and a second fluorescent moiety. The second fluorescent moiety is typically a quencher, and the fluorescent label is usually located at each end of the probe. Molecular beacon technology uses probe oligonucleotides having sequences that allow secondary structure formation (e.g., hairpins). As a result of secondary structure formation within the probe, the two fluorescent moieties are spatially close when the probe is in solution. Upon hybridization with the amplification product, the secondary structure of the probe is disrupted, and the fluorescent moieties become separated from each other, allowing the emission of the first fluorescent moieties to be detected upon excitation with light of an appropriate wavelength.
[0140] Therefore, the method according to the invention is the FRET method described above, wherein the probe contains a nucleic acid sequence that allows secondary structure formation, wherein the secondary structure formation results in spatial proximity between the first fluorescent portion and the second fluorescent portion.
[0141] Effective FRET occurs only when the fluorescent portions are directly and locally close, and when the emission spectrum of the donor fluorescent portion overlaps with the absorption spectrum of the acceptor fluorescent portion.
[0142] Therefore, in one embodiment, the donor and acceptor fluorescent portions are located on the probe within no more than 5 nucleotides of each other. In a further embodiment, the acceptor fluorescent portion is a quencher.
[0143] As mentioned above, in In this configuration, during the annealing step of the PCR reaction, the labeled hybridization probe binds to the target nucleic acid (i.e., the amplification product) and is degraded during the subsequent extension phase by the 5′ to 3′ exonuclease activity of Taq or another suitable polymerase known to those skilled in the art (such as mutant Z05 polymerase). Thus, in one embodiment, in the method described above, the amplification employs a polymerase having 5′ to 3′ exonuclease activity.
[0144] A further advantage is the careful selection of the length of the amplicon produced by the above method. Generally, relatively short amplicons increase the efficiency of the amplification reaction. Thus, one aspect of the invention is the method described above, wherein the amplified fragment contains a maximum of 450 bases, a maximum of 300 bases, a maximum of 200 bases, or a maximum of 150 bases.
[0145] A "sequence" is the primary structure of a nucleic acid, that is, the specific arrangement of the individual nucleobases that make up each nucleic acid. It must be understood that the term "sequence" does not refer to a specific type of nucleic acid such as RNA or DNA, but rather applies to both and other types of nucleic acids, such as, for example, PNA or others. As is well known in the relevant fields, where nucleobases correspond to each other, particularly in the cases of uracil (present in RNA) and thymine (present in DNA), these bases can be considered equivalent between RNA and DNA sequences.
[0146] Clinically relevant nucleic acids are often DNA, which can originate from DNA viruses, such as hepatitis B virus (HBV) and cytomegalovirus (CMV), or bacteria, such as Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). In such cases, it can be advantageous to use an internal control nucleic acid composed of DNA to reflect the properties of the target nucleic acid. The terms "cell," "cell line," and "cell culture" are used interchangeably, and all such names include progeny. Thus, the term "transformer" or "transformed cell" includes the primary transformed cell and the number of cultures derived from that cell, regardless of translocation. Due to intentional or unintentional mutations, all progeny may not be exactly identical in DNA content. The definition of a transformant includes mutant progeny with the same function as selected in the initially transformed cell. Cells can be prokaryotic or eukaryotic.
[0147] The term "control sequence" refers to the DNA sequence necessary for the expression of an operable linked coding sequence in a particular host organism. Suitable control sequences for prokaryotes include, for example, promoters, optionally operon sequences, ribosome binding sites, forward and reverse regulatory elements (see U.S. Patent No. 4,666,848, which is incorporated herein by reference), and possibly other sequences. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.
[0148] The term "operable link" refers to the location of a coding sequence such that a control sequence will function to drive the expression of the protein encoded by the coding sequence. Therefore, a coding sequence "operable link" with a control sequence represents a configuration in which the coding sequence can be expressed under the guidance of the control sequence.
[0149] The terms “restriction endonuclease” and “restriction endonuclease” refer to enzymes that are typically found in bacteria and that cut double-stranded DNA at or near a specific nucleotide sequence.
[0150] This paper defines families of amino acid residues with similar side chains. These families include amino acids with the following side chains: basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., asparagine, glutamine, serine, threonine, tyrosine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan, cysteine, glycine), β-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).
[0151] The term "reagent solution" is any solution containing at least one reagent required or used for PCR purposes. Most typical components include polymerase, nucleotides, primers, ions, magnesium, salts, pH buffers, nucleotide triphosphates (NTPs) or deoxynucleotide triphosphates (dNTPs), probes, fluorescent dyes (which can be attached to the probes), nucleic acid binding agents, and nucleic acid templates. Reagents can also be other polymerase reaction additives that affect the polymerase reaction or its monitoring.
[0152] The term "master mixture" refers to a mixture of all or most of the components or factors required for PCR to occur, and in some cases, to everything except for sample- and amplicon-specific templates and primers. Commercially available master mixtures are typically concentrated solutions. A master mixture may contain all the reagents shared by multiple samples, but it can also be constructed for only one sample. Using a master mixture helps reduce pipetting errors and variations between samples caused by differences in pipetting volumes.
[0153] The term "thermally stable polymerase" refers to an enzyme that is heat-stable, heat-resistant, and retains sufficient activity to perform subsequent primer extension reactions after being subjected to elevated temperatures for the time required for double-stranded nucleic acid denaturation. The heating conditions required for nucleic acid denaturation are well known in the art and are illustrated, for example, in U.S. Patent Nos. 4,965,188 and 4,889,818, which are incorporated herein by reference. As used herein, thermostable polymerases are suitable for use in temperature-cycled reactions, such as PCR. Examples of thermostable nucleic acid polymerases include Taq DNA polymerase from *Thermomyces spp.*, Z05 polymerase from *Thermomyces spp.*, polymerases from *Thermomyces flavomarginata*, polymerases from *Thermomyces spp.* such as TMA-25 and TMA-30 polymerases, Tth DNA polymerase, etc.
[0154] A "polymerase with reverse transcriptase activity" is a nucleic acid polymerase capable of synthesizing DNA based on an RNA template. Once the RNA has been reverse transcribed into single-stranded cDNA, it can also replicate single-stranded or double-stranded DNA. In one embodiment of the invention, the polymerase with reverse transcriptase activity is thermostable.
[0155] In RNA amplification via DNA polymerase, the first extension reaction is reverse transcription using an RNA template, producing a DNA strand. The second extension reaction using a DNA template produces a double-stranded DNA molecule. Therefore, complementary DNA strands are synthesized from an RNA template by DNA polymerase to provide the raw materials for amplification.
[0156] Thermostable DNA polymerases can be used in coupled single-enzyme reverse transcription / amplification reactions. In this context, the term "homogeneous" refers to a two-step single addition reaction for reverse transcription and amplification of an RNA target. Homogeneity means that the reaction vessel does not need to be opened or the reaction components otherwise modified after the reverse transcription (RT) step and before the amplification step. In heterogeneous RT / PCR reactions, one or more reaction components (such as amplification reagents) must be opened, or at least their contents must be manipulated, after reverse transcription and before amplification. Both homogeneous and heterogeneous examples are included within the scope of this invention.
[0157] Reverse transcription is a crucial step in RT / PCR. For example, it is known in the art that RNA templates tend to form secondary structures that can hinder primer binding and / or cDNA strand elongation via the corresponding reverse transcriptase. Therefore, the relatively high temperature of the RT reaction is advantageous in terms of transcription efficiency. On the other hand, increasing the incubation temperature also implies higher specificity, meaning that the RT primers will not anneal to sequences exhibiting mismatches with one or more expected sequences. Particularly in the case of multiple different target RNAs, it is expected that they will also be transcribed and subsequently amplified and detected with a single mismatch, for example, in situations where a substrain or subspecies of an unknown or rare organism may be present in the fluid sample.
[0158] To take advantage of the two benefits mentioned above, namely the reduction of secondary structure and reverse transcription with mismatched templates, RT incubation can be carried out at more than one different temperature.
[0159] Therefore, one aspect of the present invention is the method described above, wherein the incubation of the polymerase having reverse transcriptase activity is carried out at different temperatures of 30°C to 75°C, or 45°C to 70°C, or 55°C to 65°C.
[0160] As a further important aspect of reverse transcription, a long RT step can disrupt the DNA template that may be present in the fluid sample. If the fluid sample contains both RNA and DNA species, it is therefore advantageous to keep the duration of the RT step as short as possible, while ensuring that a sufficient amount of cDNA is synthesized for subsequent amplification and optional detection of amplification products.
[0161] Therefore, one aspect of the present invention is the method described above, wherein the time period for incubating the polymerase having reverse transcriptase activity is up to 30 minutes, 20 minutes, 15 minutes, 12.5 minutes, 10 minutes, 5 minutes or 1 minute.
[0162] A further aspect of the invention is the method described above, wherein the polymerase having reverse transcriptase activity and containing a mutation is selected from:
[0163] a) CS5 DNA polymerase
[0164] b) CS6 DNA polymerase
[0165] c) Thermotoga maritima DNA polymerase
[0166] d) DNA polymerase of *Thermus aquaticus*
[0167] e) Thermus thermophilus DNA polymerase
[0168] f) Thermus flavus DNA polymerase
[0169] g) DNA polymerase of *Thermus filiformis*
[0170] h) DNA polymerase of *Thermus* sp. sp. 17 species
[0171] i) Thermus sp. Z05 DNA polymerase
[0172] j) DNA polymerase of *Thermotoga neapolitana*
[0173] k) Termosporium africanus DNA polymerase
[0174] l) Thermus caldophilus DNA polymerase
[0175] Particularly suited to these requirements are enzymes that carry mutations in the polymerase domain that enhance their reverse transcription efficiency in terms of faster elongation rates.
[0176] Therefore, in the above method, the polymerase having reverse transcriptase activity is an enzyme that includes a mutation, which confers an improved nucleic acid elongation rate and / or improved reverse transcriptase activity relative to the corresponding wild-type polymerase.
[0177] In one embodiment, in the above method, the polymerase having reverse transcriptase activity is an enzyme comprising a mutation that confers improved reverse transcriptase activity relative to the corresponding wild-type polymerase.
[0178] WO 2008 / 046612 discloses polymerases carrying point mutations, which make them particularly useful. Specifically, the polymerase to be used can be a mutant DNA polymerase that contains at least the following motifs in its polymerase domain:
[0179] TGRLSS-Xb7-Xb8-PNLQN; wherein Xb7 is an amino acid selected from S or T, and Xb8 is an amino acid selected from G, T, R, K, or L, wherein the polymerase contains 3′-5′ exonuclease activity and has an improved nucleic acid elongation rate and / or improved reverse transcription efficiency relative to the wild-type DNA polymerase, wherein in the wild-type DNA polymerase, Xb8 is an amino acid selected from D, E, or N.
[0180] One example is a mutant of a thermostable DNA polymerase from *Thermus* species Z05 (described, for example, in US 5,455,170), the mutation comprising a mutation in the polymerase domain compared to the corresponding wild-type enzyme Z05. One embodiment for use in the method according to the invention is a mutant Z05 DNA polymerase wherein the amino acid at position 580 is selected from the groups G, T, R, K, and L.
[0181] For reverse transcription using thermostable polymerases, divalent cations (such as Mn) are typically included in the form of salts. 2+ or Mg 2+ Examples of manganese chloride (MnCl2), manganese acetate (Mn(OAc)2), or manganese sulfate (MnSO4), or magnesium chloride (MgCl2), magnesium acetate (Mg(OAc)2), or magnesium sulfate (MgSO4). If MnCl2 is included in a reaction containing 50 mM Tricine buffer, it is typically present at a concentration of 0.5–7.0 mM; when using 200 μM each of dGTP, dATP, dUTP, and dCTP, it is typically present at 2.5–3.5 mM.
[0182] A “modified” thermostable polymerase is a polymerase in which at least one monomer differs from a reference sequence, such as a polymerase in its natural or wild-type form or another modified form. Exemplary modifications include monomer insertion, deletion, and substitution. Modified polymerases also include chimeric polymerases having identifiable component sequences (e.g., structural or functional domains) derived from two or more parents. The definition of a modified polymerase also includes those with chemical modifications that incorporate a reference sequence. Examples of modified thermostable polymerases include G46E E678G CS5 DNA polymerase, G46E L329A E678G CS5 DNA polymerase, G46E L329A D640G S671F CS5 DNA polymerase, G46EL329A D640G S671F E678G CS5 DNA polymerase, G46E E678G CS6 DNA polymerase, Z05 DNA polymerase, ΔZ05 polymerase, ΔZ05-Gold polymerase, ΔZ05R polymerase, E615G Taq DNA polymerase, E678G TMA-25 polymerase, and E678G TMA-30 polymerase.
[0183] The term "thermally active polymerase" refers to an enzyme that is active at the high temperatures (e.g., 55-80°C) necessary to ensure specific initiation and primer extension.
[0184] The terms “peptide,” “polypeptide,” and “protein” are used interchangeably. The terms “nucleic acid” and “polynucleotide” are used interchangeably. Unless otherwise specified, the amino acid sequence is written from the amino terminus to the carboxyl terminus. Unless otherwise specified, the single-stranded nucleic acid sequence is written from 5′ to 3′. Unless otherwise specified, the upper strand of a double-stranded nucleic acid sequence is written from 5′ to 3′, and the lower strand from 3′ to 5′.
[0185] While the foregoing has been described in considerable detail for clarity and understanding, those skilled in the art will recognize from this disclosure that various changes in form and detail may be made without departing from the true scope of the invention. For example, all the foregoing compositions and methods may be used in various combinations. All publications, patents, patent applications and / or other documents referenced in this application are incorporated herein by reference in their entirety for all purposes, to the extent that each individual publication, patent, patent application and / or other document is individually indicated to be incorporated by reference for all purposes.
[0186] The chemical structure numbers of the compounds disclosed in this application are shown below:
[0187] Silicon and germanium aniline / azacyclobutane
[0188]
[0189]
[0190] dibromide
[0191]
[0192]
[0193]
[0194] imidazole
[0195]
[0196] Imidazole dyes
[0197]
[0198]
[0199] Imidazolium dyes
[0200]
[0201]
[0202] Example
[0203] The following examples illustrate embodiments of the invention, as are currently preferred. It should be understood that these examples are illustrative and the invention should not be considered limiting except as indicated in the appended claims.
[0204] Abbreviations: abs. = anhydrous, AcOH = acetic acid, aq. = aqueous, dATP = 2′-deoxyadenosine 5′-triphosphate, dCTP = 2′-deoxycytidine 5′-triphosphate, dGTP = 2′-deoxyguanosine 5′-triphosphate, DBCO = dibenzocyclooctylene modified; DCM = dichloromethane, DMF = N,N′-dimethylformamide, DMSO = dimethyl sulfoxide, dUTP = 2′-deoxyuridine 5′-triphosphate, eq. = molar equivalent, Et2O = diethyl ether, EtOAc = ethyl acetate, MeCN = acetonitrile, MeOH = methanol, qPCR = real-time polymerase chain reaction, RT = room temperature, SPE = solid phase extraction, TBAF = tetrabutylammonium fluoride, THF = tetrahydrofuran, TLC = thin layer chromatography, UPLC-MS = ultra-high performance liquid chromatography-mass spectrometry.
[0205] General Materials and Methods
[0206] Unless otherwise specified, all reagents were purchased from Millipore Sigma (Burlington, MA, USA). Tert-butyllithium solution (1.5 M, in n-pentane) was obtained from Alfa Aesar (Haverhill, MA, USA). 1-(3-bromophenyl)azacyclobutane and methyl 1-butyl-1H-imidazolium-2-carboxylate were obtained from ChemShuttle (Hayward, CA, USA). Methyl 1-methyl-1H-imidazolium-2-carboxylate was obtained from AA Blocks LLC (San Diego, CA, U.SA). Methyl 1,4,5-trimethyl-1H-imidazolium-2-carboxylate was obtained from ChemSpace (Monmouth Junction, NJ, USA). 2-(trimethylsilyl)phenyl trifluoromethanesulfonate was obtained from TCI America (Porrland, Oregon, USA). 1-Azide-2-(2-(2-(2-bromoethoxy)ethoxy)ethoxy)ethane (bromo-PEG3-azide) was obtained from BroadPharm (San Diego, CA, USA). Reagents and materials used in chemical DNA synthesis were obtained from Glen Research (Sterling, VA, USA).
[0207] Unless otherwise specified, all synthetic transformations were performed in flame-dried glassware under a dry argon atmosphere. Solvents used in the chemical reactions were obtained from Acros Organics (Thermo Fisher Scientific, Waltham, MA, USA) and stored on activated molecular sieves. Chromatographic solvents (HPLC grade) were obtained from MilliporeSigma or VWR (Radnor, PA, USA) and were used without further purification. Microwave-assisted reactions were performed using CEM (Matthews, NC, USA). The reaction was conducted using an SP microwave system equipped with a focused single-mode reaction chamber (2.45 GHz) in thick-walled glass vials (2.0 mL or 10.0 mL). The reaction temperature was monitored using a built-in infrared temperature sensor and maintained constant via automatic power control. Microwave-assisted stirring was performed under active cooling conditions using compressed air. An automated rapid chromatography system from Teledyne-Isco (Lincoln, NE, USA) was used. Rf + Rapid column chromatography separation was performed using Lumen. UPLC analysis was performed using a diode array, fluorescence and mass spectrometry (ZSpray) system. TMThe detector was performed using a Waters I-class ACQUITY UPLC (Waters Corporation, Milford, MA, USA). A Waters BEH C18 oligonucleotide analysis column was used. MeCN was used in combination with TEAA buffer (100 mM, pH 7.0) or H2O (0.1% formic acid) at a flow rate of 1.0 ml / min (1.7 μm, 2.1 × 50 mm). Semi-preparative HPLC purification was performed using a 996 photodiode array detector and a Waters XBridge. TM BEH C18 OBD Prep column ( The sample was analyzed on a Waters 600 HPLC system (5 μm, 19.0 × 250 mm) at a flow rate of 10.0 mL / min. Before injection, the sample was filtered through a Teflon syringe filter (0.20 μm). Absorption spectra were obtained using an Agilent 8453 UV-Vis spectrophotometer (Santa Clara, CA, USA). Fluorescence spectra were recorded using an Agilent Cary Eclipse fluorescence spectrophotometer.
[0208] Depending on the appropriate post-treatment or purification method, compounds carrying one or more positive charges (24-36) are obtained in the form of acetate, chloride, bromide, or iodide salts. Substitution of the anti-charged ions is achieved through standard ion exchange procedures using suitable ion exchange resins, liquid-liquid extraction, or precipitation from organic solvents.
[0209] Example 1: General Procedure for a Reaction Scheme
[0210] Figure 5A general reaction scheme for preparing the fluorescent dyes according to the present invention is provided. As shown in the figure, the method for preparing the fluorescent dyes includes the step of forming a dye core. In this document, a dihalogen-metal exchange is performed on a dihalogen (1) with an organolithium reagent, such as tert-butyllithium, to obtain the corresponding dilithium compound. Subsequently, the intermediate (“in situ”) is reacted with an alkyl ester (e.g., methyl 1-alkyl- or 1-aryl-1H-imidazolium-2-carboxylate (2)). Subsequently, a Brønsted acid (“one-pot reaction”), such as acetic acid, is added to remove water from the hydroxyl intermediate to perform aromatization to obtain compound (3). After the dye core formation reaction, the imidazole is quaternized to imidazolium. In some aspects, the imidazole (3) is quaternized to imidazolium compounds by nucleophilic substitution with an alkyl halide, alkyl toluenesulfonate, alkyl trifluoromethanesulfonate, or alkyl methanesulfonate to obtain alkylated compounds (4). In other respects, the quaternization of imidazole (3) to imidazole-onium compounds is carried out with a cyclic lactone (e.g., β-propiolactone) in the presence of a Lewis acid (e.g., aluminum tribromide) to give formic acid (5). In still other respects, 3-imidazole nitrogen (3) is quaternized to imidazole-onium using an arylynylene generated in situ from a 2-(trimethylsilyl)phenyl trifluoromethanesulfonate reagent and a fluoride donor, such as tetrabutylammonium fluoride or tetra-n-butylammonium difluorotriphenylsilicate, to give an arylated compound (6).
[0211] Example 2: General procedure for synthesizing compounds 1-10
[0212]
[0213] Where X = Si, Ge; Y = Me, iPr, Ph; Z = NMe2, NC3H6.
[0214] Compounds 1-10 [3,3′-(dimethylsilanediyl)bis(N,N-dimethylaniline) 1, bis(3-(azacyclobutane-1-yl)phenyl)dimethylsilane 2, 3,3′-(diisopropylsilanediyl)bis(N,N-dimethylaniline) 3, bis(3-(azacyclobutane-1-yl)phenyl)diisopropylsilane 4, 3,3′-(diphenylsilanediyl)bis(N,N-dimethylaniline) 5, bis(3-(azacyclobutane-1-yl)phenyl)diphenylsilane 6, 3,3′-(dimethylgermanyl)diyl] The following compounds are synthesized from 3-bromo-N,N-dimethylaniline or 1-(3-bromophenyl)azacyclobutane and the corresponding silane or germane reagent (selected from dichlorodimethylsilane, dichlorodiisopropylsilane, dichlorodiphenylsilane, dimethylgermanium dichloride or diphenylgermanium dichloride).
[0215] A solution of 3-bromo-N,N-dimethylaniline or 1-(3-bromophenyl)azacyclobutane (2,4 eq.) in dry THF (17.0 mL) was cooled to -78 °C, and then a solution of n-butyllithium (2,4 eq., 2.5 M, in hexane) was slowly and dropwise added. The reaction mixture was stirred at -78 °C for 0.5 h. At the same temperature, a solution of the corresponding silane or germane (1.0 eq., 4.0 mmol) in THF (2.2 mL) was added. Subsequently, the cooling bath was removed, and the reaction mixture was stirred at RT for 3 h, or until TLC analysis (silica gel, EtOAc / hexane) showed complete conversion of the starting material. The reaction was quenched with saturated NH4Cl (5.0 mL), diluted with H2O (20 mL), and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous MgSO4, and filtered. The solvent was evaporated, and the residue was dried under high vacuum. The crude product was purified by rapid silica gel chromatography (silica gel, 0-10% EtOAc in hexane) to give the title compound as a colorless oil. Analysis was performed by NMR and UPLC-MS (C2C3). 18 The properties of the product were confirmed by adding H2O, 0.1% formic acid, and MeCN (which increased from 50% to 100% in 2.0 minutes).
[0216] Example 3: General procedure for synthesizing compounds 11-20
[0217]
[0218] Where X = Si, Ge; Y = Me, iPr, Ph; Z = NMe2, NC3H6.
[0219] Compounds 11-20 [3,3′-(dimethylsilanediyl)bis(4-bromo-N,N-dimethylaniline) 11, bis(5-(azacyclobutan-1-yl)-2-bromophenyl)dimethylsilane 12, 3,3′-(diisopropylsilanediyl)bis(4-bromo-N,N-dimethylaniline) 13, bis(5-(azacyclobutan-1-yl)-2-bromophenyl)diisopropylsilane 14, 3,3′-(diphenylsilanediyl)bis(4-bromo-N,N-dimethylaniline) 15, The compounds 16, 3,3′-(dimethylgermanyl)bis(4-bromo-N,N-dimethylaniline) 17, 18, 19, and 20 are synthesized from compounds 1-10.
[0220] Aniline or aziridine (1.0 eq., 3.0 mmol) was dissolved in dry DMF (18.9 mL) and cooled in an ice bath. N-bromosuccinamide (2.02 eq.) was added over 0.5 h with stirring. The reaction was stirred at room temperature for 3 h, or until TLC analysis (silica gel, EtOAc / hexane) showed complete conversion of the starting material. The mixture was diluted with DCM and extracted twice with a semi-saturated aqueous NaHCO3 solution. The organic layer was washed with a saturated aqueous NaCl solution, dried over MgSO4, and filtered. The solvent was evaporated, and the residue was dried under high vacuum. The pure product was obtained by rapid chromatography (silica gel, 0-10% EtOAc in hexane) or recrystallization. Analysis by NMR and UPLC-MS (C60- ... 18 The properties of the product were confirmed by adding H2O, 0.1% formic acid, and MeCN (which increased from 50% to 100% in 2.0 minutes).
[0221] Example 4: General Procedure for Synthesizing Dyes 24-28
[0222]
[0223] Where X = Si, Ge; Y = Me, iPr, Ph; Z = NMe2, NC3H6; R = Me, Bu.
[0224] Dyes 24-28 are synthesized from compounds 11, 12, 20 and the corresponding imidazole methyl esters 21-23 [methyl 1H-imidazolium-2-carboxylate 21, methyl 1,4,5-trimethyl-1H-imidazolium-2-carboxylate 22, methyl 1-butyl-1H-imidazolium-2-carboxylate 23].
[0225] The solution of the corresponding dibromide (1.0 eq., 450 μmol) in anhydrous THF (5.75 mL) was cooled to -78 °C. A solution of tert-butyllithium (4.4 eq., 1.5 M, in n-pentane) was added dropwise, and the reaction mixture was stirred at -78 °C for 30 min. The reaction temperature was raised to -20 °C, and then the solution of the corresponding imidazolidinyl ester (2.2 eq.) in anhydrous THF (5.75 mL) was slowly added over 0.5 h. The mixture was stirred at RT for 18 h. The pH of the reaction mixture was set to 4.0 with glacial acetic acid, and the solution was stirred at RT for 4 h, during which a distinct blue color formed. The reaction mixture was extracted with saturated KBr aqueous solution and DCM. The combined organic layers were washed with H2O, dried over Na2SO4, and filtered. The solvent was evaporated under reduced pressure. The residue was redissolved in a minimal amount of DCM and added to a stirred solution of Et2O. The formed blue precipitate was separated and washed by centrifugation. The yellow supernatant was discarded. The deep blue dye was dried under high vacuum and then analyzed by semi-preparative HPLC (C6000-2000 ppm). 18 Purification was performed using TEAA / MeCN.
[0226] Example 5: General procedure for synthesizing dyes 29 and 30
[0227]
[0228] Where Z = NMe2, NC3H6.
[0229] Imidazolium dyes 29 and 30 were synthesized from dyes 24 and 25, respectively.
[0230] A solution of imidazole dye (1.0 eq., 17 μmol) and iodomethane (2.0 eq.) in MeCN was heated to 80 °C by microwave irradiation for 6 h. The reaction mixture was added to stirred Et₂O. The precipitate was separated by centrifugation, and the supernatant was discarded. Finally, the precipitate was analyzed by semi-preparative HPLC (C0). 18 The crude product was purified using TEAA / MeCN. The fluorescence spectrum and temperature dependence of fluorescence are as follows: Figure 1 As shown.
[0231] Example 6: Procedure for synthesizing dye 31
[0232]
[0233] A solution of imidazole dye (1.0 eq., 17 μmol, final concentration 30 mM) and 2-(trimethylsilyl)phenyl trifluoromethanesulfonate (5.0 eq.) in anhydrous MeCN was prepared, and dried TBAF (1.0 M, in THF, 5.0 eq.) was added last to initiate the reaction. The stirred solution was heated at 50 °C for 1.0 h by microwave irradiation. UPLC-MS analysis (MeCN increased from 30% to 60% within 2 minutes) confirmed the completion of the reaction. The mixture was poured into a stirred Et2O container, and solid NaI (2.0 eq.) was added. The formed precipitate was separated by centrifugation. The supernatant was discarded and the residue was absorbed into H2O. Insoluble byproducts were removed using a Teflon syringe filter and analyzed by semi-preparative HPLC (C2O2). 18 Imidazolium dyes were obtained from the supernatant using TEAA (30-60% MeCN).
[0234] Example 7: General Procedure for Synthesizing Dyes 32-35
[0235]
[0236] Where X = Si, Ge; R1 = Me, Bu; R2 = H, Me.
[0237] Solutions of imidazole dye (1.0 eq., 20 μmol, final concentration 78 mM) and β-propiolactone (10.0 eq.) in anhydrous MeCN were prepared, with AlBr3 added last to initiate the reaction. The solution was stirred at RT for 1.0 h, during which some precipitate formed. UPLC-MS analysis (MeCN increased from 30% to 60% within 2 min) confirmed the completion of the reaction. The mixture was poured into a stirred Et2O container. The formed precipitate was separated by centrifugation. The residue was washed with Et2O, dried under high vacuum, and redissolved in MeCN (400 μL). TEAA buffer (3.6 mL) was added, and insoluble byproducts were removed using a Teflon syringe filter. The reaction was analyzed by semi-preparative HPLC (C10-C20-C20). 18 Imidazolium dyes were obtained from the supernatant using TEAA (30-60% MeCN).
[0238] Example 8: Procedure for synthesizing dye 36
[0239]
[0240] A solution of imidazole dye (1.0 eq., 17 μmol, final concentration 50 mM), bromo-PEG 3-azide (2.0 eq.), and NaI (10.0 eq.) in anhydrous MeCN was heated at 50 °C for 12 h. This precipitated the product from Et₂O and was analyzed by semi-preparative HPLC (C0). 18Purification was performed using TEAA (25%-45% MeCN). The purified product was then desalted using SPE.
[0241] Example 9: Preparation of dye-labeled DNA probes
[0242] Dye-labeled DNA probes were prepared by strain-promoted cycloaddition of azide-alkyne between DNA-bound DBCO and an azide-modified dye. Therefore, 30-mer DNA probes containing a 3′-C3 extension inhibitor, internal BHQ-2, and 5′-DBCO dT modification were prepared via solid-phase DNA synthesis and purified using standard methods. DNA (1.0 eq., 100 μM, 50 mM TEAA) and dye azide #36 (1.1 eq., 100 μM, 50 mM TEAA) were mixed and incubated on a shaker at RT for 2 h. DNA conjugates with a commercially available reference dye (azide-modified) were prepared in the same manner. Any excess dye was completely removed by ethanol precipitation using standard procedures. UPLC analysis showed quantitative labeling of the DNA. Figure 2A and 2B ).
[0243] Example 10: PCR amplification using dye-labeled DNA probes
[0244] All qPCR components were prepared using nuclease-free H2O. A total reaction mixture of 50 μL was prepared by mixing three components: a master mixture (20 μL), a buffer mixture (20 μL), and a dNTP mixture (10 μL). The master mixture contained Tricine buffer (pH 8.2), manganese acetate, potassium acetate, glycerol, DMSO, detergent, target DNA (5000 copies / reaction), polymerase aptamer, labeled DNA probe, forward and reverse primer DNA, and polymerase. The dNTP mixture contained dATP, dCTP, dGTP (2.0 mM each), and dUTP (4.0 mM). Each qPCR was prepared in triplicate in the wells of a 96-well plate. The plate was sealed and used… The 480 system (Fritz Hofmeister AG, Basel, Switzerland) was used to conduct amplification cycles. Growth curves were analyzed based on fluorescence data acquired in the Cy5.5 channel, and as... Figure 3 As shown.
[0245] Example 11: Immunohistochemical tissue staining
[0246] Dyes azide No. 36 and CF680R were used for staining tonsil tissue sections. CONFIRM was used. TMFormalin-fixed paraffin-embedded tissue sections were treated with anti-Ki-67(30-9) rabbit monoclonal primary antibody (Ventana Medical Systems, Inc., Tucson, Az, USA) and labeled with the corresponding dye azide at a concentration of 200 μM. Optical microscopic images at 10x, 20x, and 40x magnification are shown below. Figure 4 As shown.
Claims
1. A fluorescent dye of formula A or B Formula A Formula B in: X = Si, Ge, or C; Y = Me, Et, iPr, or Ph; Z = any of the following: ; W = any of the following: ; R1 and R2 are any combination of the following terms: And L = H, CONH2, CO2H or N3.
2. The fluorescent dye according to claim 1, wherein Z = 。 3. The fluorescent dye according to any one of claims 1 to 2, wherein the dye is selected from the group consisting of: 。 4. A method for preparing a fluorescent dye according to any one of claims 1 to 3, the method comprising the following steps: a) Perform dihalogen-metal exchange on dihalides using an organolithium reagent to obtain the corresponding dilithium compounds; b) React the dilithium compound with an alkyl ester to form a hydroxyl intermediate; c) Adding Brønsted acid to the hydroxyl intermediate to perform aromatization by eliminating water to form an imidazole; as well as d) Quaternize the imidazole to imidazoleium.
5. The method of claim 4, wherein quaternization is performed by nucleophilic substitution with an alkyl halide, alkyl toluenesulfonate, alkyl trifluoromethanesulfonate or alkyl methanesulfonate.
6. The method of claim 4, wherein the quaternization is performed with a cyclic lactone in the presence of a Lewis acid.
7. The method of claim 4, wherein the quaternization is performed using an aromatic yne generated in situ from a 2-(trimethylsilyl)phenyl trifluoromethanesulfonate reagent and a fluoride donor.
8. A method for detecting the presence of one or more target nucleic acids in a sample in a polymerase chain reaction (PCR) assay, wherein the detection is performed by: - Contact the sample with an oligonucleotide probe labeled with at least one fluorescent dye according to any one of claims 1 to 3; and - Measure the fluorescence signal generated by the labeled oligonucleotide, thereby detecting the fluorescence signal to indicate the presence of one or more target nucleic acids in the sample. This method is not intended for diagnostic purposes.
9. The method according to claim 8, wherein the polymerase chain reaction (PCR) assay is a multiplex polymerase chain reaction (PCR) assay.
10. The method according to any one of claims 8 or 9, wherein the measurement of the fluorescence signal occurs at a temperature of 65°C or higher.
11. A method for detecting the presence of one or more target proteins in a tissue sample in an immunohistochemical assay, wherein the detection is performed by: - Contact the tissue sample with a binding entity labeled with at least one fluorescent dye according to any one of claims 1 to 3, the binding entity interacting directly or indirectly with the target protein; and - To reveal the fluorescent signal generated in the tissue sample, thereby indicating the presence of one or more target proteins in the tissue sample upon detection of the fluorescent signal. This method is not intended for diagnostic purposes.
12. The method of claim 11, wherein the binding entity is a first antibody that binds to the one or more target proteins or a second antibody that binds to the first antibody.
13. Use of an oligonucleotide probe labeled with at least one fluorescent dye according to any one of claims 1-3 for preparing a reagent for a method of detecting the presence of one or more target nucleic acids in a sample in a polymerase chain reaction (PCR) assay, the method being performed by: - Contact the sample with an oligonucleotide probe labeled with at least one fluorescent dye according to any one of claims 1 to 3; and - Measure the fluorescence signal generated by the labeled oligonucleotide, thereby the detection of the fluorescence signal indicates the presence of one or more target nucleic acids in the sample.
14. The use according to claim 13, wherein the polymerase chain reaction (PCR) assay is a multiplex polymerase chain reaction (PCR) assay.
15. The use according to any one of claims 13 or 14, wherein the measurement of the fluorescence signal occurs at a temperature of 65°C or higher.
16. Use of a binding entity labeled with at least one fluorescent dye according to any one of claims 1-3 for preparing a reagent for use in an immunohistochemical assay to detect the presence of one or more target proteins in a tissue sample, the method being performed by: - Contact the tissue sample with a binding entity labeled with at least one fluorescent dye according to any one of claims 1 to 3, the binding entity interacting directly or indirectly with the target protein; and - To reveal the fluorescent signal generated in the tissue sample, thereby indicating the presence of one or more target proteins in the tissue sample upon detection of the fluorescent signal.
17. The use according to claim 16, wherein the binding entity is a first antibody that binds to the one or more target proteins or a second antibody that binds to the first antibody.
Citation Information
Patent Citations
Improved method of amplifying target nucleic acids applicable to both polymerase and ligase chain reactions
EP0439182A2
New pentacyclic compounds and their use as absorption or fluorescence dyestuffs
EP0543333A1
Methods for performing multiplexed PCR
US20180073056A1
Methods for performing multiplexed real-time PCR
US20180073064A1
Polypeptide expression using a portable temperature sensitive control cassette with a positive retroregulatory element
US4666848A
